Research Progress on Eradication of Helicobacter pylori with Tegoprazan Regimen
Abstract：Helicobacter pylori (Hp) is highly prevalent in the population, with a global infection rate of 43.1%, and the overall prevalence rate of Hp in mainland China is 44.2% [1]. Existing studies have found that Hp infection is associated with various digestive system diseases such as gastric adenocarcinoma, peptic ulcer, chronic active gastritis, and MALT lymphoma, as well as many extragastrointestinal diseases [2-3]. Eradicating Hp is currently a primary measure for preventing gastric cancer. Current international consensus indicates that all Hp-infected individuals should receive eradication therapy regardless of symptoms and/or complications [4-6].
Keywords：Helicobacter pyloriTegoprazanproton pump inhibitorseradicationresistance
Publication Date：2025-07-01
Online Publishing Date：2025-09-04(First online date of this platform, not the publication date of the document)
Pages：7( 619-625 )